

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

INRP:074/SLH

09/526,320

Applicants

Dmitry Gabrilovich et al.

Filing Date:

March 15, 2000

Group:

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 2

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
<i>AC</i>	B6	WO 98/06863	2-19-98	PCT			
	B7	WO 99/26662	6-3-99	PCT			
	B8	WO 99/27958	6-10-99	PCT			
<i>AC</i>	B9	WO 99/47180	9-23-99	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>AC</i>	C1	Austin-Ward, Villaseca, "Gene therapy and its applications," <i>Rev. Med. Chil.</i> , 126(7):838-45, 1998.
	C2	Bertholet <i>et al.</i> , "Cytotoxic T lymphocyte responses to wild-type and mutant mouse p53 peptides," <i>Eur. J. Immunol.</i> , 27(3):798-801, 1997.
	C3	Bukowski <i>et al.</i> , "Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy," <i>Clin. Cancer Res.</i> , 4(10):2337-47, 1998.
	C4	Caley <i>et al.</i> , "Venezuelan equine encephalitis virus vectors expressing HIV-1 proteins: vector design strategies for improved vaccine efficacy," <i>Vaccine</i> , 17:3124-35, 1999.
	C5	Celluzzi and Falò, "Epidermal dendritic cells induce potent antigen-specific CTL-mediated immunity," <i>J. Invest. Dermatol.</i> , 108:716-720, 1997.
	C6	Christodoulides <i>et al.</i> , "Immunization with recombinant class 1 outer-membrane protein from <i>Neisseria meningitidis</i> : influence of liposomes and adjuvants on antibody avidity, recognition of native protein and the induction of a bactericidal immune response against meningococci," <i>Microbiology</i> , 144:3027-37, 1998.
	C7	Ciernik <i>et al.</i> , "Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes," <i>J. Immunol.</i> , 156:2369-75, 1996.
	C8	Davidson <i>et al.</i> , "Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma," <i>J. Immunother.</i> , 21:389-98, 1998.
<i>AC</i>	C9	DeLeo, "p53-based immunotherapy of cancer," <i>Crit. Rev. Immunol.</i> , 18:29-35, 1998.

4555806.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.


Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

INRP:074/SLH
09/526,320**List of Patents and Publications for Applicant's****INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

Applicants
Dmitry Gabrilovich et al.**Filing Date:**
March 15, 2000**Group:**
Unknown**U.S. Patent Documents***See Page 1***Foreign Patent Documents***See Page 1***Other Art***See Page 2***Documents**

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	5,633,016	05-27-97	Johnson	424	649	05-01-95
	A2	5,643,786	07-01-97	Cohen	435	325	01-27-95
	A3	5,648,219	07-15-97	MacKay <i>et al.</i>	435	6	6-7-95
	A4	5,739,169	4-14-98	Ocain <i>et al.</i>	514	658	5-31-96
	A5	5,747,469	5-5-98	Roth <i>et al.</i>	514	44	4-24-94
	A6	5,788,963	8-4-98	Murphy <i>et al.</i>	424	93.21	7-31-95
	A7	5,798,339	8-25-98	Brandes	514	34	7-28-93
	A8	5,801,005	9-1-98	Cheever <i>et al.</i>	435	7.24	3-31-95
	A9	5,811,297	9-22-98	Gopal	435	320.1	3-7-96
	A10	5,824,311	10-20-98	Greene <i>et al.</i>	424	138.1	11-30-94
	A11	5,824,346	10-20-98	Dugan	424	649	8-22-96
	A12	5,830,682	11-3-98	Moore	435	29	12-13-96
	A13	5,830,880	11-3-98	Sedlacek <i>et al.</i>	514	44	4-18-97
	A14	5,846,945	12-8-98	McCormick	514	44	6-7-95
✓	A15	5,849,589	12-15-98	Tedder <i>et al.</i>	435	377	3-11-96

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	EP 0273085	7-6-88	Europe			
	B2	WP 94/11514	5-26-94	PCT			
	B3	WO 97/00954	1-9-97	PCT			
	B4	WO 97/03703	2-6-97	PCT			
✓	B5	WO 97/29183	8-14-97	PCT			

4555806.1

EXAMINER: *DLP*DATE CONSIDERED: *4/14/01*

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

INRP:074/SLH

09/526,320

Applicants

Dmitry Gabrilovich et al.

Filing Date:

March 15, 2000

Group:

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
DIC	C10	Dupuis <i>et al.</i> , "Dendritic cells internalize vaccine adjuvant after intramuscular injection," <i>Cell Immunol.</i> , 186:18-27, 1998.
	C11	Gabrilovich <i>et al.</i> , "Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts," <i>Cell Immunol.</i> , 170:101-10, 1996.
	C12	Gabrilovich <i>et al.</i> , "Decreased antigen presentation by dendritic cells in patients with breast cancer," <i>Clin. Cancer Res.</i> , 3(3):483-490, 1997.
	C13	Gabrilovich <i>et al.</i> , "Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors," <i>Cell Immunol.</i> , 170(1):111-119, 1996.
	C14	Gabrilovich <i>et al.</i> , "IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer," <i>J. Immunother.</i> , 19:414-418, 1996.
	C15	Hanibuchi <i>et al.</i> , "Therapeutic efficacy of mouse-human chimeric antiganglioside GM2 monoclonal antibody against multiple organ micrometastases of human lung cancer in NK cell-depleted SCID mice," <i>Int. J. Cancer</i> , 78(4):480-485, 1998.
	C16	Hellstrand <i>et al.</i> , "Histamine and cytokine therapy," <i>Acta Oncol.</i> , 37(4):347-53, 1998.
	C17	Hui and Hashimoto, "Pathways for potentiation of immunogenicity during adjuvant-assisted immunizations with Plasmodium falciparum major merozoite surface protein 1," <i>Infect. Immun.</i> , 66(11):5329-36, 1998.
	C18	Hurpin <i>et al.</i> , "The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity," <i>Vaccine</i> , 16:208-215, 1998.
	C19	Mayordomo <i>et al.</i> , "Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines," <i>J. Exp. Med.</i> , 183(4):1357-1365, 1996.
	C20	McCarty <i>et al.</i> , "Sequences required for coordinate induction of adeno-associated virus p19 and p40 promoters by rep protein," <i>J. Virol.</i> , 65:2936-2945, 1991.
	C21	Nijman <i>et al.</i> , "p53, a potential target for tumor-directed T cells," <i>Immunol. Letters</i> , 40:171-178, 1994.
	C22	Pietras <i>et al.</i> , "Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs," <i>Oncogene</i> , 17(17):2235-49, 1998.

4555806.1

EXAMINER:

DATE CONSIDERED:

9/19/01

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

INRP:074/SLH

09/526,320

Applicants

Dmitry Gabrilovich et al.

Filing Date:

March 15, 2000

Group:

Unknown

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 1

Other Art

See Page 2

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>All</i>	C23	Racher <i>et al.</i> , "Culture of 293 cells in different culture systems: cell growth and recombinant adenovirus production," <i>Biotechnology Techniques</i> , 9:169-174, 1995.
<i>✓</i>	C24	Raz <i>et al.</i> , "Intradermal gene immunization: The possible role of DNA uptake in the induction of cellular immunity to viruses," <i>Proc. Natl. Acad. Sci.</i> , 91:9519-9523, 1994.
<i>✓</i>	C25	Ropke <i>et al.</i> , "Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide," <i>Proc. Natl. Acad. Sci. USA</i> , 93:14704-14707, 1996.
<i>✓</i>	C26	Saurwein-Teissl <i>et al.</i> , "Whole virus influenza vaccine activates dendritic cells (DC) and stimulates cytokine production by peripheral blood mononuclear cells (PBMC) while subunit vaccines support T cell proliferation," <i>Clin. Exp. Immunol.</i> , 114(2):271-276, 1998.
<i>✓</i>	C27	Sonderbye <i>et al.</i> , " <i>In vivo</i> and <i>in vitro</i> modulation of immune stimulatory capacity of primary dendritic cells by adenovirus-mediated gene transduction," <i>Exp. Clin. Immunogenet.</i> , 15(2):100-111, 1998.
<i>✓</i>	C28	Steinman, "The dendritic cell system and its role in immunogenecity," <i>Annu. Rev. Immunol.</i> , 9:271-296, 1991.
<i>✓</i>	C29	Theobald <i>et al.</i> , "Targeting p53 as a general tumor antigen," <i>Proc. Natl. Acad. Sci. USA</i> , 92:11993-11997, 1995.
<i>✓</i>	C30	Wan <i>et al.</i> , "Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination," <i>Hum. Gene. Ther.</i> 8:1355-1363, 1997.
<i>✓</i>	C31	Yanuck <i>et al.</i> , "A mutant p53 tumor suppressor protein is a target for peptide-induced CD8 ⁺ cytotoxic T-cells," <i>Cancer Res.</i> , 53(14):3257-61, 1993.
<i>✓</i>	C32	Yu <i>et al.</i> , "Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients," <i>Clin. Can. Res.</i> , 7:127-135, 2001.
<i>✓</i>	C33	Zitrogel <i>et al.</i> , "Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines," <i>J. Exp. Med.</i> , 183:87-97, 1996.

4555806.1

EXAMINER:

M. Obell

DATE CONSIDERED:

9/19/01

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.